91��ɫ

The national specialty group is lead jointly by (University Hospitals Coventry & Warwickshire),  (University Hospital Birmingham) and  (Papworth Hospital). 91��ɫ areas of focus include cardiovascular disease prevention, atherothrombosis, arrhythmias, cardiac surgery, congenital heart disease, pulmonary arterial hypertension and heart failure.

Find out more you can visit our website at:

Access our Study Support Service online at:

The , lead by  (University of Sheffield), includes nationally and internationally recognised key opinion leaders, all of whom are active researchers, who provide strategic input into enabling people with diabetes to participate in high quality clinical studies which are delivered to time and target.

has had a long association with the NIHR to injecting new ideas and innovation into diabetes research, which is good news for the 4 million people in the UK living with diabetes. We work closely with the , to support the emerging thinking and outputs of each of the seven groups.

Find out more you can visit our website at:

Access our Study Support Service online at:

The , led by , is one of 30 specialties which bring together communities of clinical practice to provide networks of research expertise and clinical leadership. It is made up of research-interested clinicians and practitioners who work at both national and local levels to ensure the studies that are included in our portfolio of research are delivered successfully in the NHS. 

Nutrition

The Gastroenterology specialty have recognised a deficit in the nutritional research activity on the NIHR portfolio as well as being underrepresented in funding calls. This applies not only to disease-specific areas such as IBD, coeliac disease and IBS, but also to nutritional support and obesity.

We would like to pull together a small sub-group of key experts and representatives from complementary speciatiles to identify if there is any appetite to plan and run a cross-specialty, cross-disciplinary workshop focusing on the overarching question of 'What do we need to do to increase the volume of, and capacity and capability for, nutritional research?'.

Find out more you can visit our website at: 

Access our Study Support Service online at: 

The , led by , is one of 30 specialties which bring together communities of clinical practice to provide networks of research expertise and clinical leadership. It is made up of research-interested clinicians and practitioners who work at both national and local levels to ensure the studies that are included in our portfolio of research are delivered successfully in the NHS. 

Our current research focus areas include; 

Liver disease related to alcohol and obesity
A cross-specialty, cross-NIHR, cross-institution project to review how we can better develop and deliver studies relating to the multiple causes of liver disease, specifically focusing on alcohol and obesity.

There are three components to the course:

• Hands on involvement with your local research team – gain experience in the delivery of NIHR portfolio studies and recruiting patients via the NIHR Associate PI Scheme
• Online course – covering the principles and practice of clinical research, statistics and critical appraisal
• Group event – converting clinical problems into research questions (2nd November 2022) 

Please see the Clinical 91��ɫ Training programme flyer.pdf which includes information on how to register interest, and further details on the course itself.

 
Access our Study Support Service online at: 

The , lead by (University of Liverpool), is comprised of nationally and internationally recognised key opinion leaders who are principal or chief investigators for many studies. We also have representation from major national charities, including the .

Our research focus areas support a wide range of studies such as those involving adrenal glands and associated diseases, thyroid problems, the pituitary gland, metabolic bone disease, nutrition including obesity, polycystic ovarian syndrome, reproductive endocrinology, and many rare inherited conditions affecting these systems and other aspects of metabolism.

Find out more you can visit our website at:

Access our Study Support Service online at:

The , led by  (University College London), is comprised of leading research-interested clinicians and practitioners at both national and local levels. We cover the entire renal disorders care pathway across all subspecialty areas, including benign Urology.

CRN Renal Disorders benefits from consistent and innovative interaction with other key renal stakeholders, especially its main charity, and the academic body, . In 2006 the specialty helped to develop UK’s first renal research .

Find out more you can visit our website at:

Access our Study Support Service online at:

The , led by  (in post from 1st September 2023), is one of 30 specialties which bring together communities of clinical practice to provide networks of research expertise and clinical leadership. It is made up of research-interested clinicians and practitioners who work at both national and local levels to ensure the studies that are included in our portfolio of research are delivered successfully in the NHS. 

The current research focus include: 

Acute Respiratory Infections (ARI)
A cross, speciality, cross NIHR, and organisational project to develop a platform approaches to support studies ARI across the UK, bridging primary and secondary care.

The INSPIRE Respiratory Early Career 91��ɫer (ECR) Network aims to create a vibrant, dynamic and inclusive community to facilitate a collaborative approach to perform clinical research and high-quality audits on a national scale for the benefit of patients with respiratory disease.

In the process of establishing and conducting these research activities, members will develop their research skills, gain career mentorship and establish and strengthen regional and national collaborations between institutions, and between specialties.

The network and steering committee will have access to a senior counsel consisting of a panel of established senior clinical academics who can provide advice and guidance on the suitability of proposed projects and audits, and other aspects of running the network.

A sandpit event will be held in 2023 for ECRs to pitch research proposals for the network to support and deliver nationally. Further details on the Sandpit Event will be shared in due course.

For more information about the network please visit the .

Find out more you can visit our website at: 

Access our Study Support Service online at: 

The , lead by  (Newcastle University), is made up of key opinion leaders across the UK with specific skills and expertise to support and delivered stroke studies. We cover the entire stroke pathway, from the first few hours after stroke, until months and years later. 91��ɫ areas of focus in stroke have included hyperacute, recovery, rehabilitation and prevention.

Find out more you can visit our website at:

Access our Study Support Service online at:

An ATMP is a medicinal product which is either i) a gene therapy, ii) a somatic cell therapy, or iii) a tissue engineered product. There are currently ~90 ATMP trials ongoing in the UK, and ~1000 worldwide. The Cluster undertook scoping to identify challenges that may be contributing to the low number of trials in the UK, identifying:

• Lack of specialised training across multiple groups
• Restricted access to infrastructure and lack of clarity as to the infrastructure needed
• Clarifying the role of pharmacy professionals
• No single industry offering

However, the biggest challenge related to the number of enthusiastic stakeholders duplicating each other’s work. Our simple solution has been to pull together a NIHR ATMP Coordinating Group chaired by Cluster A and including all relevant stakeholders (Figure).

Working Groups deliver the day-to-day business and include (lead):

Education and workforce (Uta Griesenbach, Professor of Molecular Medicine at 91��ɫ College and British Society for Gene and Cell Therapy President): Developing training and educational programmes and activities for the entire workforce impacted by ATMP studies.

Pan UK ATMP Pharmacy (Anne Black, Regional QA Specialist Pharmacist and Nicola Stoner, Cancer Consultant Pharmacist): Developing guidelines and providing expertise on pharmacy processes and pathways required for ATMP studies.

Infrastructure and Governance (Joanna Gray, UK Clinical 91��ɫ Facility Clinical Manager, Birmingham): Ensuring that NHS Trusts have the necessary infrastructure and knowledge required to be involved in ATMP studies

Industry (Madina Kara, NOCRI Senior 91��ɫ Collaboration Manager): Developing a single ATMP offering for the UK, which can be used by all industry entry points.

Patient and Public Involvement and Engagement (Jayne Spink, CEO, Genetic Alliance UK): Aiming to enable members of the public and patients to become more aware of and involved in ATMP studies.

Metabolic phenotyping is a scientific research strategy to understand the interactions between the genotype, environment and lifestyle at the molecular level - the strategy allows us to study metabolomics, the study of the complete set of metabolites within biological fluids, tissues or organisms.  

By studying the metabolome, researchers can measure the dynamics of the cell response which may in turn support the identification of active biological pathways during disease/health.  An important use of this information might be to better predict disease outcomes or treatment response to particular drug regimes.

The medical and scientific community are well aware of the potential applications of metabolomics. One imagines a wide variety of research questions could be addressed, but what are the techniques used to produce metabolomic data? How does one interpret it and make comparisons with it? How can one incorporate the techniques into a research proposal? What are the analysis options best suited to answer a given research hypothesis?  Many questions quickly emerge and researchers may not easily find answers or guidance.

We are collaborating with staff from the (NPC) based at 91��ɫ and also the to broaden the use of metabolic phenotyping in the clinical research community.  We have produced a free in metabolomics which covers the basics of the analytical techniques used and the mathematical principles which make sense of the data produced. The course comprises 14 short videos in total and includes practical aspects of sample selection, preparation, experimental and study design and biomarker identification. The course is aimed at clinicians, research nurses and practitioners.  Those who complete the course and want to take the next step in incorporating the technique in their research are encouraged to contact our collaborators at NPC.

Our current project involves producing a cloud-based reference tool against which researchers can analyse and compare their own metabolomic data.  We plan to provide reference metabolomic profiles of healthy and common disease populations so that researchers do not have to spend a significant portion of their funding on analysing ‘control’ samples.

Medical technology is an extremely broad field and we have been focussing our energy on medical devices. We started by examining the current “landscape” for different types of devices and how they relate to clinical conditions. In collaboration with , we produced a report on  which charts the changing role of devices from a clinician’s tool to those entirely operated by patients. Biomarkers and multi-parameter measurements can detect the likelihood of exacerbations and in turn aid disease management and reduce hospital admission.

A second report on ‘’ highlights the current state-of-the-art devices which form the basis of current treatments such as stenting, embolisation and ablation.